This is not a reliable source or information - it’s more sensationalized than even most journalism.
Better review article, here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360730/?tool=pubmed
There won’t be an “efficacy study” in 11 and 12 year olds, because it is assumed that they are not sexually active. In fact, the apparent efficacy statistic will be skewed toward less effective by adding these girls.
However, the goal is to separate first sexual contact with the vaccine (this isn’t the sex vaccine) and to have a wider coverage because we catch them before they are exposed. Not only that, but the younger girls have a stronger immune response by making more antibodies (not more adverse effects) and younger girls under 18 are also more likely to catch the virus when exposed than older women because of the type of cells that make up their cervix.
Even in 2006, we knew that the vaccine gave at least 5 years immunity.
25% of 11 and 12 year old girls have received at least one dose of Gardisil in the US. The reactions are similar to the same conditions in the general population, except for frequency of fainting and clotting problems.
http://www.lifeethics.org/www.lifeethics.org/uploaded_images/JAMA-VAERS-report-HPV-Aug-09-765766.JPG